23.9 C
New York
Monday, June 21, 2021

Zydus Cadila gets USFDA nod for orthostatic hypotension drug

Must read

REC shares decline 0.44% as Sensex slides

A total of 91,640 shares changed hands on the counter till 11:58AM (IST)

Netflix: Will 2021 Be A Dead Year For This Streaming Giant’s Stock?

Video-streaming giant, Netflix (NASDAQ:NFLX) has been one of the strongest equity performers during the pandemic. The company and its stock benefited from the stay-at-home...

PNB Housing tanks 5% as Sebi halts Carlyle deal

PNB Housing Finance has reached the Securities Appellate Tribunal (SAT), filing an appeal against the letter by Sebi.

Indian Oil Corp. shares fall 1.02% as Nifty drops

A total of 349,974 shares changed hands on the counter till time (IST).

New Delhi: Drug firm Zydus Cadila has received final approval from the US health regulator to market Midodrine Hydrochloride tablets, used to treat orthostatic hypotension.

The drug is used for certain patients who have symptoms of low blood pressure when standing. This condition is also known as orthostatic hypotension.

Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Midodrine Hydrochloride tablets in the strengths of 2.5 mg, 5 mg, and 10 mg, Cadila Healthcare said in a regulatory filing.

Zydus Cadila is a part of Cadila Healthcare group.

The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 298 approvals and has so far filed over 390 Abbreviated New Drug Application (ANDAs) since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 384.60 apiece on BSE, 0.69 per cent higher against their previous close.

- Advertisement -

Latest article

REC shares decline 0.44% as Sensex slides

A total of 91,640 shares changed hands on the counter till 11:58AM (IST)

Netflix: Will 2021 Be A Dead Year For This Streaming Giant’s Stock?

Video-streaming giant, Netflix (NASDAQ:NFLX) has been one of the strongest equity performers during the pandemic. The company and its stock benefited from the stay-at-home...

PNB Housing tanks 5% as Sebi halts Carlyle deal

PNB Housing Finance has reached the Securities Appellate Tribunal (SAT), filing an appeal against the letter by Sebi.

Indian Oil Corp. shares fall 1.02% as Nifty drops

A total of 349,974 shares changed hands on the counter till time (IST).

Buy TTK Prestige, target price Rs 9897: Anand Rathi

TTK Prestige Ltd., incorporated in the year 1955, is a Mid Cap company (having a market cap of Rs 12017.84 Crore) operating in Consumer...